igf-1 lr3 receptor grade vs media grade Late-life targeting of the improves healthspan and lifespan in female mice Receptor Grade IGF-1 LR3 Peptide

Considering the notion has been raised that sub-clinical presentation of konzo exists, these measures may allow for the identification of individuals who show similar reduced antioxidant capacity as those with konzo, but who do not show a visible physical disability, enabling the overdue refinement of the clinical features associated with this disease 3,42

Nutrients 2010, 2 (7), 693-724

Structural Selectivity: The peptides structure determines its function

Development Note: Cagrilintide is currently in Phase 3 clinical trials (REDEFINE program) and has not yet received regulatory approval

The barrier will still be an investigational new drug application in an FDA designated disease indication (of which for many of these peptide use cases, there isn't one)

doi: 10.1111/pcn.13016 98 MorroniF.TarozziA.SitaG.BolondiC.Zolezzi MoragaJ